Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate
clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal …

The current conceptualization of Alzheimer disease (AD) is driven by the amyloid
hypothesis, in which a deterministic chain of events leads from amyloid deposition and then …

Background The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may
initiate or potentiate pathologic processes in Alzheimer's disease. Lecanemab, a humanized …

Importance There are limited efficacious treatments for Alzheimer disease. Objective To
assess efficacy and adverse events of donanemab, an antibody designed to clear brain …

Background Alzheimer's disease is a progressive, irreversible, and fatal disease for which
accumulation of amyloid beta is thought to play a key role in pathogenesis. Aducanumab is …

Background Trials of monoclonal antibodies that target various forms of amyloid at different
stages of Alzheimer's disease have had mixed results. Methods We tested solanezumab …

Immunotherapy against amyloid-beta (Aβ) is a promising option for the treatment of
Alzheimer's disease (AD). Aβ exists as various species, including monomers, oligomers …

Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …

Abstract Background Lecanemab, a humanized IgG1 monoclonal antibody that targets
soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid …

Background Deposition of tau aggregates is a pathological hallmark of Alzheimer's disease
that is closely linked both spatially and temporally to emergence of neurodegeneration and …